Monte Rosa Therapeutics Key Executives
This section highlights Monte Rosa Therapeutics's key executives, including their titles and compensation details.
Find Contacts at Monte Rosa Therapeutics
(Showing 0 of )
Monte Rosa Therapeutics Earnings
This section highlights Monte Rosa Therapeutics's earnings, including key dates, EPS, earnings reports, and earnings call transcripts.
Next Earnings Date
Last Earnings Results
Earnings Call Transcripts
| Transcript | Quarter | Year | Date | Estimated EPS | Actual EPS |
|---|---|---|---|---|---|
| Read Transcript | Q4 | 2024 | 2025-03-20 | $-0.37 | $0.23 |
Financial Statements
Access annual & quarterly financial statements for Monte Rosa Therapeutics, including income statements, balance sheets, and cash flow statements..
Annual Income Statement
| Breakdown | December 31, 2024 | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 |
|---|---|---|---|---|---|
| Revenue | $75.62M | $- | $- | $- | $- |
| Cost of Revenue | $8.12M | $6.22M | $8.56M | $2.13M | $537.00K |
| Gross Profit | $67.50M | $-6.22M | $-8.56M | $-2.13M | $-537.00K |
| Gross Profit Ratio | 89.26% | - | - | - | - |
| Research and Development Expenses | $121.56M | $105.05M | $85.06M | $57.16M | $24.00M |
| General and Administrative Expenses | $35.17M | $32.04M | $27.32M | $15.73M | $4.00M |
| Selling and Marketing Expenses | $- | $- | $- | $- | $- |
| Selling General and Administrative Expenses | $35.17M | $32.04M | $27.32M | $15.73M | $4.00M |
| Other Expenses | $- | $- | $- | $-960.00K | $-7.68M |
| Operating Expenses | $156.73M | $143.31M | $112.38M | $72.88M | $28.01M |
| Cost and Expenses | $156.73M | $143.31M | $112.38M | $72.88M | $28.01M |
| Interest Income | $10.57M | $9.33M | $3.76M | $46.00K | $9.00K |
| Interest Expense | $- | $- | $3.76M | $- | $- |
| Depreciation and Amortization | $8.12M | $6.22M | $8.56M | $2.13M | $537.00K |
| EBITDA | $-72.99M | $-137.09M | $-99.94M | $-70.75M | $-27.47M |
| EBITDA Ratio | -96.52% | - | - | - | - |
| Operating Income | $-81.11M | $-143.31M | $-112.38M | $-72.88M | $-28.01M |
| Operating Income Ratio | -107.26% | - | - | - | - |
| Total Other Income Expenses Net | $10.98M | $8.30M | $3.88M | $-1.08M | $-7.87M |
| Income Before Tax | $-70.13M | $-135.01M | $-108.50M | $-73.96M | $-35.88M |
| Income Before Tax Ratio | -92.74% | - | - | - | - |
| Income Tax Expense | $2.57M | $338.00K | $-3.88M | $-2.02M | $189.00K |
| Net Income | $-72.70M | $-135.35M | $-104.62M | $-71.94M | $-36.07M |
| Net Income Ratio | -96.14% | - | - | - | - |
| EPS | $-0.98 | $-2.63 | $-2.22 | $-1.55 | $-0.82 |
| EPS Diluted | $-0.98 | $-2.63 | $-2.22 | $-1.55 | $-0.82 |
| Weighted Average Shares Outstanding | 73.91M | 51.40M | 47.23M | 46.54M | 44.00M |
| Weighted Average Shares Outstanding Diluted | 73.91M | 51.40M | 47.23M | 46.54M | 44.00M |
| SEC Filing | Source | Source | Source | Source | Source |
| Breakdown | December 31, 2024 | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $60.65M | $9.22M | $4.70M | $1.06M | $8.75M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Cost of Revenue | $2.06M | $- | $2.06M | $1.90M | $1.85M | $1.83M | $1.39M | $1.15M | $2.68M | $2.58M | $2.17M | $1.13M | $809.00K | $582.00K | $467.00K | $274.00K | $- | $- | $- | $- |
| Gross Profit | $58.59M | $9.22M | $2.63M | $-833.00K | $6.91M | $-1.83M | $-1.39M | $-1.15M | $-2.68M | $-2.58M | $-2.17M | $-1.13M | $-809.00K | $-582.00K | $-467.00K | $-274.00K | $- | $- | $- | $- |
| Gross Profit Ratio | 96.60% | 100.00% | 56.12% | -78.29% | 78.91% | - | - | - | - | - | - | - | - | - | - | - | 0.00% | 0.00% | 0.00% | 0.00% |
| Research and Development Expenses | $36.80M | $27.62M | $26.00M | $25.13M | $25.29M | $28.31M | $29.08M | $26.75M | $24.87M | $21.34M | $20.94M | $17.91M | $18.13M | $15.12M | $14.64M | $9.27M | $9.86M | $5.47M | $4.86M | $3.81M |
| General and Administrative Expenses | $8.78M | $8.13M | $9.28M | $8.98M | $7.73M | $8.66M | $8.14M | $7.50M | $7.62M | $7.02M | $6.29M | $6.39M | $5.26M | $4.75M | $3.49M | $2.23M | $2.07M | $914.00K | $541.00K | $478.00K |
| Selling and Marketing Expenses | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Selling General and Administrative Expenses | $8.78M | $8.13M | $9.28M | $8.98M | $7.73M | $8.66M | $8.14M | $7.50M | $7.62M | $7.02M | $6.29M | $6.39M | $5.26M | $4.75M | $3.49M | $2.23M | $2.07M | $914.00K | $541.00K | $478.00K |
| Other Expenses | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $-960.00K | $- | $- | $- | $- |
| Operating Expenses | $47.64M | $35.74M | $35.28M | $34.11M | $33.02M | $36.97M | $37.22M | $34.26M | $32.49M | $28.36M | $27.23M | $24.30M | $23.39M | $19.87M | $18.12M | $11.50M | $11.94M | $6.39M | $5.40M | $4.29M |
| Cost and Expenses | $47.64M | $35.74M | $37.34M | $36.01M | $34.86M | $36.97M | $37.22M | $34.26M | $32.49M | $28.36M | $27.23M | $24.30M | $23.39M | $19.87M | $18.12M | $11.50M | $11.94M | $6.39M | $5.40M | $4.29M |
| Interest Income | $2.60M | $2.89M | $2.64M | $2.44M | $2.37M | $2.23M | $2.30M | $2.44M | $1.99M | $997.00K | $628.00K | $149.00K | $13.00K | $13.00K | $14.00K | $6.00K | $9.00K | $2.00K | $1.00K | $- |
| Interest Expense | $- | $- | $- | $- | $935.00K | $- | $- | $- | $1.99M | $997.00K | $628.00K | $149.00K | $- | $- | $- | $- | $9.00K | $- | $- | $3.00K |
| Depreciation and Amortization | $2.06M | $2.10M | $2.06M | $1.90M | $1.85M | $1.83M | $1.39M | $1.15M | $2.68M | $2.58M | $2.17M | $1.13M | $809.00K | $582.00K | $467.00K | $274.00K | $223.00K | $171.00K | $72.00K | $71.00K |
| EBITDA | $15.06M | $-24.42M | $-30.58M | $-33.05M | $-33.02M | $-35.13M | $-35.83M | $-33.11M | $-31.42M | $-27.33M | $-26.34M | $-23.55M | $-22.58M | $-19.29M | $-17.66M | $-11.23M | $-11.71M | $-6.21M | $-5.32M | $-4.23M |
| EBITDA Ratio | 24.84% | -265.02% | -651.37% | -3106.20% | -377.25% | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Income | $13.00M | $-26.53M | $-32.64M | $-34.95M | $-34.86M | $-36.97M | $-37.22M | $-34.26M | $-32.49M | $-28.36M | $-27.23M | $-24.30M | $-23.39M | $-19.87M | $-18.12M | $-11.50M | $-11.94M | $-6.39M | $-5.40M | $-4.29M |
| Operating Income Ratio | 21.44% | -287.84% | -695.25% | -3284.49% | -398.34% | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Total Other Income Expenses Net | $2.60M | $2.74M | $2.58M | $3.06M | $1.59M | $2.25M | $2.23M | $2.22M | $1.71M | $1.04M | $762.00K | $370.00K | $-53.00K | $31.00K | $-282.00K | $-772.00K | $-7.72M | $-172.00K | $32.00K | $-9.00K |
| Income Before Tax | $15.60M | $-23.79M | $-30.06M | $-31.89M | $-33.27M | $-34.71M | $-34.99M | $-32.04M | $-30.78M | $-27.32M | $-26.47M | $-23.93M | $-23.44M | $-19.84M | $-18.41M | $-12.28M | $-19.66M | $-6.56M | $-5.36M | $-4.30M |
| Income Before Tax Ratio | 25.72% | -258.12% | -640.21% | -2996.71% | -380.19% | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Income Tax Expense | $2.16M | $71.00K | $252.00K | $83.00K | $-22.00K | $-170.00K | $190.00K | $-2.22M | $-1.71M | $-1.04M | $-762.00K | $-370.00K | $-756.00K | $-613.00K | $282.00K | $-188.00K | $40.00K | $172.00K | $-32.00K | $3.00K |
| Net Income | $13.44M | $-23.86M | $-30.31M | $-31.97M | $-33.25M | $-34.88M | $-35.18M | $-29.82M | $-29.07M | $-26.27M | $-25.71M | $-23.56M | $-23.44M | $-19.84M | $-18.41M | $-12.28M | $-19.66M | $-6.56M | $-5.36M | $-4.30M |
| Net Income Ratio | 22.16% | -258.89% | -645.58% | -3004.51% | -379.94% | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| EPS | $0.22 | $-0.29 | $-0.43 | $-0.53 | $-0.58 | $-0.70 | $-0.71 | $-0.60 | $-0.59 | $-0.56 | $-0.55 | $-0.51 | $-0.51 | $-0.43 | $-3.63 | $-0.29 | $-0.90 | $-0.30 | $-0.25 | $-0.20 |
| EPS Diluted | $0.22 | $-0.29 | $-0.43 | $-0.53 | $-0.58 | $-0.70 | $-0.71 | $-0.60 | $-0.59 | $-0.56 | $-0.55 | $-0.51 | $-0.51 | $-0.43 | $-3.63 | $-0.29 | $-0.90 | $-0.30 | $-0.25 | $-0.20 |
| Weighted Average Shares Outstanding | 61.44M | 82.01M | 71.23M | 60.16M | 56.93M | 49.81M | 49.43M | 49.35M | 48.89M | 46.73M | 46.67M | 46.60M | 45.99M | 45.99M | 5.07M | 42.54M | 21.74M | 21.74M | 21.74M | 21.74M |
| Weighted Average Shares Outstanding Diluted | 61.44M | 82.01M | 71.23M | 60.16M | 56.93M | 49.81M | 49.43M | 49.35M | 48.89M | 46.73M | 46.67M | 46.60M | 45.99M | 45.99M | 5.07M | 42.54M | 21.74M | 21.74M | 21.74M | 21.74M |
| SEC Filing | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source |
Annual Balance Sheet
| Breakdown | December 31, 2024 | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 |
|---|---|---|---|---|---|
| Cash and Cash Equivalents | $224.25M | $128.10M | $54.91M | $346.07M | $41.70M |
| Short Term Investments | $147.90M | $104.31M | $207.91M | $- | $- |
| Cash and Short Term Investments | $372.15M | $232.41M | $262.83M | $346.07M | $41.70M |
| Net Receivables | $173.00K | $505.00K | $7.66M | $- | $- |
| Inventory | $- | $- | $960.00K | $- | $- |
| Other Current Assets | $5.12M | $3.29M | $5.40M | $5.19M | $1.79M |
| Total Current Assets | $377.44M | $236.21M | $275.89M | $348.67M | $43.59M |
| Property Plant Equipment Net | $56.31M | $62.61M | $61.91M | $12.32M | $4.62M |
| Goodwill | $- | $- | $- | $- | $- |
| Intangible Assets | $- | $- | $- | $- | $- |
| Goodwill and Intangible Assets | $- | $- | $- | $- | $- |
| Long Term Investments | $- | $- | $4.32M | $5.34M | $1.16M |
| Tax Assets | $- | $- | $- | $- | $- |
| Other Non-Current Assets | $4.98M | $4.93M | $278.00K | $- | $- |
| Total Non-Current Assets | $61.29M | $67.54M | $66.50M | $17.66M | $5.79M |
| Other Assets | $- | $- | $- | $- | $- |
| Total Assets | $438.73M | $303.75M | $342.39M | $366.33M | $49.38M |
| Account Payables | $17.21M | $11.15M | $7.86M | $6.56M | $7.07M |
| Short Term Debt | $3.71M | $3.16M | $6.25M | $- | $- |
| Tax Payables | $- | $- | $- | $- | $- |
| Deferred Revenue | $117.23M | $17.68M | $- | $- | $- |
| Other Current Liabilities | $18.79M | $14.60M | $11.45M | $10.08M | $22.21M |
| Total Current Liabilities | $156.95M | $46.59M | $25.57M | $16.64M | $29.27M |
| Long Term Debt | $- | $42.88M | $43.87M | $- | $67.76M |
| Deferred Revenue Non-Current | $- | $32.32M | $- | $- | $1.07M |
| Deferred Tax Liabilities Non-Current | $- | $- | $- | $- | $- |
| Other Non-Current Liabilities | $58.85M | $2.71M | $1.53M | $2.18M | $- |
| Total Non-Current Liabilities | $58.85M | $77.91M | $45.41M | $2.18M | $68.83M |
| Other Liabilities | $- | $- | $- | $- | $- |
| Total Liabilities | $215.80M | $124.50M | $70.98M | $18.81M | $98.11M |
| Preferred Stock | $- | $- | $- | $366.33M | $67.76K |
| Common Stock | $6.00K | $5.00K | $5.00K | $5.00K | $1.00K |
| Retained Earnings | $-438.59M | $-365.89M | $-230.54M | $-122.03M | $-48.08M |
| Accumulated Other Comprehensive Income Loss | $-3.36M | $-2.72M | $-1.75M | $-2.02M | $-1.06M |
| Other Total Stockholders Equity | $664.87M | $547.86M | $503.70M | $471.57M | $404.00K |
| Total Stockholders Equity | $222.94M | $179.25M | $271.41M | $347.51M | $-48.73M |
| Total Equity | $222.94M | $179.25M | $271.41M | $347.51M | $-48.73M |
| Total Liabilities and Stockholders Equity | $438.73M | $303.75M | $342.39M | $366.33M | $49.38M |
| Minority Interest | $- | $- | $- | $- | $- |
| Total Liabilities and Total Equity | $438.73M | $303.75M | $342.39M | $366.33M | $49.38M |
| Total Investments | $147.90M | $104.31M | $207.91M | $5.34M | $1.16M |
| Total Debt | $42.72M | $46.04M | $47.00M | $- | $67.76M |
| Net Debt | $-181.54M | $-82.06M | $-7.91M | $-346.07M | $26.07M |
Balance Sheet Charts
| Breakdown | December 31, 2024 | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | March 31, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and Cash Equivalents | $224.25M | $125.58M | $108.85M | $99.75M | $128.10M | $59.05M | $47.03M | $51.85M | $54.91M | $112.39M | $103.66M | $138.31M | $346.07M | $367.03M | $357.06M | $168.44M | $41.70M | $-6.00M |
| Short Term Investments | $147.90M | $116.61M | $153.36M | $93.14M | $104.31M | $119.42M | $156.04M | $179.89M | $207.91M | $159.75M | $190.48M | $178.86M | $- | $- | $- | $- | $- | $11.99M |
| Cash and Short Term Investments | $372.15M | $242.19M | $262.20M | $192.89M | $232.41M | $178.48M | $203.07M | $231.73M | $262.83M | $272.15M | $294.14M | $317.16M | $346.07M | $367.03M | $357.06M | $168.44M | $41.70M | $6.00M |
| Net Receivables | $173.00K | $595.00K | $9.84M | $601.00K | $505.00K | $294.00K | $1.15M | $2.17M | $7.66M | $17.56M | $- | $- | $- | $- | $- | $- | $- | $- |
| Inventory | $- | $- | $1 | $- | $- | $- | $- | $960.00K | $960.00K | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Current Assets | $5.12M | $8.43M | $5.85M | $5.54M | $3.29M | $4.14M | $3.88M | $6.65M | $5.40M | $5.53M | $5.80M | $6.41M | $5.19M | $6.97M | $2.42M | $3.19M | $1.79M | $- |
| Total Current Assets | $377.44M | $251.21M | $277.90M | $199.04M | $236.21M | $182.91M | $208.10M | $240.56M | $275.89M | $295.24M | $297.05M | $320.37M | $348.67M | $370.52M | $358.29M | $171.71M | $43.59M | $6.00M |
| Property Plant Equipment Net | $56.31M | $58.81M | $61.14M | $62.46M | $62.61M | $64.40M | $65.69M | $63.80M | $61.91M | $57.92M | $62.31M | $20.31M | $12.32M | $11.80M | $8.92M | $7.73M | $4.62M | $- |
| Goodwill | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Intangible Assets | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Goodwill and Intangible Assets | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Long Term Investments | $- | $- | $4.87M | $4.86M | $4.58M | $4.52M | $4.53M | $4.32M | $4.32M | $4.30M | $5.32M | $5.33M | $5.34M | $1.73M | $1.73M | $1.16M | $- | $- |
| Tax Assets | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Non-Current Assets | $4.98M | $5.07M | $209.00K | $389.00K | $352.00K | $270.00K | $291.00K | $351.00K | $278.00K | $148.00K | $384.00K | $- | $- | $- | $- | $- | $1.16M | $-6.00M |
| Total Non-Current Assets | $61.29M | $63.87M | $66.22M | $67.71M | $67.54M | $69.19M | $70.51M | $68.47M | $66.50M | $62.37M | $68.01M | $25.64M | $17.66M | $13.53M | $10.65M | $8.90M | $5.79M | $-6.00M |
| Other Assets | $- | $- | $1 | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Assets | $438.73M | $315.08M | $344.11M | $266.75M | $303.75M | $252.10M | $278.62M | $309.03M | $342.39M | $357.60M | $365.06M | $346.00M | $366.33M | $384.05M | $368.94M | $180.60M | $49.38M | $- |
| Account Payables | $17.21M | $3.98M | $6.47M | $6.83M | $11.15M | $5.50M | $5.31M | $7.38M | $7.86M | $9.75M | $4.29M | $4.51M | $6.56M | $3.53M | $7.46M | $7.33M | $7.07M | $- |
| Short Term Debt | $3.71M | $3.65M | $6.94M | $3.35M | $6.32M | $5.76M | $5.33M | $5.78M | $6.25M | $6.13M | $5.32M | $3.05M | $- | $- | $- | $- | $- | $- |
| Tax Payables | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Deferred Revenue | $117.23M | $18.92M | $19.64M | $20.41M | $17.68M | $11.32M | $8.66M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Current Liabilities | $18.79M | $15.10M | $9.29M | $10.71M | $11.44M | $11.35M | $8.45M | $7.35M | $11.45M | $5.91M | $5.16M | $4.93M | $10.08M | $9.21M | $3.33M | $1.76M | $22.21M | $- |
| Total Current Liabilities | $156.95M | $41.64M | $42.35M | $41.29M | $46.59M | $22.61M | $19.09M | $20.52M | $25.57M | $21.79M | $14.77M | $12.49M | $16.64M | $12.74M | $10.79M | $9.09M | $29.27M | $- |
| Long Term Debt | $39.00M | $40.05M | $40.88M | $41.84M | $42.88M | $43.52M | $44.37M | $43.27M | $43.87M | $42.59M | $46.09M | $5.46M | $- | $- | $- | $231.17M | $- | $- |
| Deferred Revenue Non-Current | $16.15M | $- | $33.60M | $28.53M | $32.32M | $1.45M | $1.50M | $1.51M | $- | $2.13M | $2.14M | $2.18M | $- | $2.00M | $1.47M | $956.00K | $- | $- |
| Deferred Tax Liabilities Non-Current | $- | $- | $- | $- | $- | $-1.45M | $-1.50M | $-1.51M | $- | $-2.13M | $-2.14M | $-2.18M | $- | $- | $- | $-232.13M | $- | $- |
| Other Non-Current Liabilities | $3.70M | $27.93M | $2.61M | $2.57M | $2.71M | $1.45M | $1.50M | $1.51M | $1.53M | $2.13M | $2.14M | $2.18M | $2.18M | $2.00M | $1.47M | $- | $68.83M | $- |
| Total Non-Current Liabilities | $58.85M | $67.98M | $77.09M | $72.93M | $77.91M | $44.97M | $45.87M | $44.79M | $45.41M | $44.72M | $48.23M | $7.64M | $2.18M | $2.00M | $1.47M | $232.13M | $68.83M | $- |
| Other Liabilities | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Liabilities | $215.80M | $109.62M | $119.44M | $114.23M | $124.50M | $67.58M | $64.96M | $65.30M | $70.98M | $66.51M | $63.01M | $20.13M | $18.81M | $14.74M | $12.26M | $241.22M | $98.11M | $- |
| Preferred Stock | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $384.05M | $368.94M | $231.17M | $67.76M | $18.95M |
| Common Stock | $6.00K | $6.00K | $6.00K | $5.00K | $5.00K | $5.00K | $5.00K | $5.00K | $5.00K | $5.00K | $5.00K | $5.00K | $5.00K | $5.00K | $4.00K | $1.00K | $1.00K | $- |
| Retained Earnings | $-438.59M | $-452.02M | $-428.17M | $-397.86M | $-365.89M | $-332.64M | $-297.75M | $-262.57M | $-230.54M | $-199.75M | $-172.44M | $-145.97M | $-122.03M | $-98.59M | $-78.76M | $-60.35M | $-48.08M | $- |
| Accumulated Other Comprehensive Income Loss | $-3.36M | $-2.32M | $-2.67M | $-2.69M | $-2.72M | $-1.46M | $-1.64M | $-1.39M | $-1.75M | $-2.60M | $-2.46M | $-2.13M | $-2.02M | $-1.95M | $-1.42M | $-920.00K | $-1.06M | $-12.15M |
| Other Total Stockholders Equity | $664.87M | $659.80M | $655.50M | $553.06M | $547.86M | $518.61M | $513.04M | $507.69M | $503.70M | $493.44M | $476.94M | $473.97M | $471.57M | $469.85M | $436.85M | $656.00K | $-67.76M | $- |
| Total Stockholders Equity | $222.94M | $205.46M | $224.67M | $152.52M | $179.25M | $184.52M | $213.65M | $243.73M | $271.41M | $291.09M | $302.05M | $325.88M | $347.51M | $369.31M | $356.68M | $-60.62M | $-48.73M | $6.80M |
| Total Equity | $222.94M | $205.46M | $224.67M | $152.52M | $179.25M | $184.52M | $213.65M | $243.73M | $271.41M | $291.09M | $302.05M | $325.88M | $347.51M | $369.31M | $356.68M | $-60.62M | $-48.73M | $6.80M |
| Total Liabilities and Stockholders Equity | $438.73M | $315.08M | $344.11M | $266.75M | $303.75M | $252.10M | $278.62M | $309.03M | $342.39M | $357.60M | $365.06M | $346.00M | $366.33M | $384.05M | $368.94M | $180.60M | $49.38M | $6.80M |
| Minority Interest | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Liabilities and Total Equity | $438.73M | $315.08M | $344.11M | $266.75M | $303.75M | $252.10M | $278.62M | $309.03M | $342.39M | $357.60M | $365.06M | $346.00M | $366.33M | $384.05M | $368.94M | $180.60M | $49.38M | $6.80M |
| Total Investments | $147.90M | $116.61M | $158.22M | $98.00M | $108.89M | $119.42M | $156.04M | $179.89M | $207.91M | $159.75M | $190.48M | $178.86M | $5.34M | $1.73M | $1.73M | $1.16M | $- | $11.99M |
| Total Debt | $42.72M | $43.70M | $44.36M | $45.18M | $46.04M | $46.40M | $47.03M | $46.16M | $47.00M | $45.66M | $48.76M | $6.98M | $- | $- | $- | $231.17M | $- | $- |
| Net Debt | $-181.54M | $-81.88M | $-64.49M | $-54.57M | $-82.06M | $-12.66M | $8.00K | $-5.68M | $-7.91M | $-66.74M | $-54.91M | $-131.32M | $-346.07M | $-367.03M | $-357.06M | $62.74M | $-41.70M | $6.00M |
Annual Cash Flow
| Breakdown | December 31, 2024 | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 |
|---|---|---|---|---|---|
| Net Income | $-72.70M | $-135.35M | $-108.50M | $-73.96M | $-35.88M |
| Depreciation and Amortization | $8.12M | $6.22M | $3.75M | $2.13M | $537.00K |
| Deferred Income Tax | $- | $- | $- | $17.00K | $- |
| Stock Based Compensation | $18.13M | $16.67M | $11.66M | $5.20M | $354.00K |
| Change in Working Capital | $91.40M | $72.47M | $-2.13M | $6.29M | $4.25M |
| Accounts Receivables | $332.00K | $1.90M | $-187 | $- | $- |
| Inventory | $- | $- | $187 | $- | $- |
| Accounts Payables | $6.25M | $5.76M | $-744.00K | $-706.00K | $3.44M |
| Other Working Capital | $84.81M | $64.81M | $-1.39M | $6.99M | $820.00K |
| Other Non Cash Items | $-2.95M | $-3.81M | $2.76M | $960.00K | $7.68M |
| Net Cash Provided by Operating Activities | $42.00M | $-43.80M | $-92.47M | $-59.36M | $-23.05M |
| Investments in Property Plant and Equipment | $-3.99M | $-19.04M | $-12.91M | $-9.73M | $-3.39M |
| Acquisitions Net | $- | $- | $109.00K | $79.00K | $- |
| Purchases of Investments | $-230.36M | $-103.15M | $-384.42M | $- | $- |
| Sales Maturities of Investments | $189.90M | $210.93M | $178.00M | $- | $- |
| Other Investing Activities | $- | $62.00K | $-206.31K | $79 | $- |
| Net Cash Used for Investing Activities | $-44.45M | $88.80M | $-219.22M | $-9.65M | $-3.39M |
| Debt Repayment | $- | $- | $- | $- | $- |
| Common Stock Issued | $944.00K | $27.49M | $20.05M | $237.75M | $60.06M |
| Common Stock Repurchased | $-641.00K | $- | $- | $- | $-440.00K |
| Dividends Paid | $- | $- | $- | $- | $- |
| Other Financing Activities | $98.59M | $27.49M | $411.00K | $139.81M | $60.50M |
| Net Cash Used Provided by Financing Activities | $98.89M | $27.49M | $20.47M | $377.56M | $60.06M |
| Effect of Forex Changes on Cash | $- | $- | $- | $- | $- |
| Net Change in Cash | $96.44M | $72.49M | $-291.22M | $308.55M | $33.62M |
| Cash at End of Period | $229.12M | $132.68M | $60.19M | $351.41M | $42.86M |
| Cash at Beginning of Period | $132.68M | $60.19M | $351.41M | $42.86M | $9.24M |
| Operating Cash Flow | $42.00M | $-43.80M | $-92.47M | $-59.36M | $-23.05M |
| Capital Expenditure | $-3.99M | $-19.04M | $-12.91M | $-9.73M | $-3.39M |
| Free Cash Flow | $38.01M | $-62.84M | $-105.38M | $-69.09M | $-26.44M |
Cash Flow Charts
| Breakdown | December 31, 2024 | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | $13.44M | $-23.86M | $-30.31M | $-31.97M | $-33.25M | $-34.88M | $-35.18M | $-32.04M | $-30.78M | $-27.32M | $-26.47M | $-23.93M | $-23.44M | $-19.84M | $-18.41M | $-12.28M | $-19.66M | $-6.56M | $-5.36M | $-4.30M |
| Depreciation and Amortization | $2.06M | $2.10M | $2.06M | $1.90M | $1.85M | $1.83M | $1.39M | $1.15M | $1.07M | $1.03M | $889.00K | $753.00K | $809.00K | $582.00K | $467.00K | $274.00K | $223.00K | $171.00K | $72.00K | $71.00K |
| Deferred Income Tax | $- | $- | $- | $- | $-2.00M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $-1.00K | $- | $- |
| Stock Based Compensation | $4.47M | $4.28M | $4.50M | $4.87M | $4.07M | $4.47M | $4.15M | $3.97M | $3.33M | $3.21M | $2.87M | $2.25M | $1.86M | $2.07M | $1.02M | $252.00K | $201.00K | $45.00K | $97.00K | $11.00K |
| Change in Working Capital | $109.65M | $15.82M | $-2.92M | $-12.90M | $57.70M | $4.37M | $5.75M | $4.64M | $2.07M | $1.27M | $1.21M | $-6.68M | $6.60M | $-625.00K | $3.34M | $-3.02M | $2.98M | $-550.00K | $983.00K | $844.00K |
| Accounts Receivables | $422.00K | $8.91M | $-9.33M | $-10.00K | $-336 | $375.00K | $-195.00K | $2.05M | $-10 | $-177 | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Inventory | $- | $- | $- | $- | $336 | $-375.00K | $195.00K | $-2.05M | $10 | $177 | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Accounts Payables | $13.31M | $-2.38M | $394.00K | $-5.07M | $5.77M | $686.00K | $-1.00M | $306.00K | $155.00K | $1.65M | $-363.00K | $-2.18M | $4.74M | $-4.25M | $-289.00K | $-906.00K | $1.93M | $-652.00K | $1.98M | $174.00K |
| Other Working Capital | $95.92M | $9.29M | $6.01M | $-7.82M | $51.94M | $3.69M | $6.75M | $4.34M | $1.92M | $-382.00K | $1.57M | $-4.50M | $1.86M | $3.63M | $3.63M | $-2.12M | $1.05M | $102.00K | $-1.00M | $670.00K |
| Other Non Cash Items | $-696.00K | $-19.34M | $16.46M | $13.68M | $1.26M | $-497.00K | $-1.44M | $-1.14M | $352.00K | $1.21M | $994.00K | $209.00K | $4.00K | $13.00K | $2.24M | $960.00K | $7.68M | $1.00K | $1.98M | $174.00K |
| Net Cash Provided by Operating Activities | $128.92M | $-20.99M | $-27.77M | $-38.16M | $29.63M | $-24.71M | $-25.32M | $-23.41M | $-23.96M | $-20.60M | $-20.50M | $-27.40M | $-14.17M | $-17.79M | $-13.58M | $-13.81M | $-8.57M | $-6.89M | $-4.21M | $-3.38M |
| Investments in Property Plant and Equipment | $-183.00K | $-399.00K | $-2.02M | $-1.38M | $-1.69M | $-1.66M | $-6.51M | $-9.18M | $-7.27M | $-1.40M | $-2.55M | $-1.69M | $-3.06M | $-1.75M | $-2.70M | $-2.22M | $-1.19M | $-930.00K | $-1.26M | $-13.00K |
| Acquisitions Net | $- | $- | $- | $- | $-15.99K | $-37.29K | $62.00K | $131.00K | $46.67K | $-16.00K | $11.70K | $125.00K | $12.00K | $67.00K | $- | $- | $- | $- | $- | $- |
| Purchases of Investments | $-67.96M | $-32.37M | $-73.96M | $-56.07M | $-27.51M | $-7.81M | $-62.00K | $-67.82M | $-94.37M | $-59.40M | $-51.70M | $-178.96M | $- | $- | $- | $- | $- | $- | $- | $- |
| Sales Maturities of Investments | $37.25M | $70.52M | $14.82M | $67.31M | $43.50M | $45.10M | $25.00M | $97.33M | $47.70M | $90.30M | $40.00M | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Investing Activities | $- | $1 | $-59.14M | $11.24M | $15.99K | $37.29K | $62.00K | $-131.00K | $-46.67K | $30.89K | $-11.70K | $125.00K | $12.00K | $67.00K | $- | $- | $- | $- | $- | $- |
| Net Cash Used for Investing Activities | $-30.90M | $37.75M | $-61.16M | $9.85M | $14.30M | $35.63M | $18.55M | $20.33M | $-53.94M | $29.49M | $-14.25M | $-180.52M | $-3.05M | $-1.69M | $-2.70M | $-2.22M | $-1.19M | $-930.00K | $-1.26M | $-13.00K |
| Debt Repayment | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Common Stock Issued | $-47.00M | $- | $98.02M | $246.00K | $25.17M | $1.10M | $1.20M | $18.00K | $20.05M | $-217.00K | $96.00K | $153.00K | $-135.00K | $31.01M | $- | $142.77M | $- | $- | $- | $- |
| Common Stock Repurchased | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $231.00K | $- | $- | $-231.00K | $- | $- | $-178.00K | $- |
| Dividends Paid | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Financing Activities | $47.61M | $656.00K | $98.02M | $246.00K | $25.17M | $1.10M | $1.20M | $18.00K | $379.00K | $-217.00K | $96.00K | $153.00K | $-135.00K | $-1.55M | $205.47M | $142.77M | $-10.00K | $47.75M | $12.32M | $- |
| Net Cash Used Provided by Financing Activities | $608.00K | $15.00K | $98.02M | $246.00K | $25.17M | $1.10M | $1.20M | $18.00K | $20.43M | $-217.00K | $96.00K | $153.00K | $-135.00K | $29.46M | $205.47M | $142.77M | $-10.00K | $47.75M | $12.32M | $- |
| Effect of Forex Changes on Cash | $- | $- | $- | $- | $-58.00K | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Net Change in Cash | $98.63M | $16.77M | $9.10M | $-28.35M | $69.05M | $12.02M | $-5.57M | $-3.06M | $-57.47M | $8.67M | $-34.65M | $-207.77M | $-17.35M | $9.97M | $189.19M | $126.74M | $-9.77M | $39.93M | $6.85M | $-3.39M |
| Cash at End of Period | $229.12M | $130.48M | $108.85M | $99.75M | $128.10M | $63.58M | $51.55M | $57.13M | $60.19M | $117.66M | $108.98M | $143.64M | $351.41M | $368.76M | $358.79M | $169.60M | $42.86M | $52.63M | $12.71M | $5.86M |
| Cash at Beginning of Period | $130.48M | $113.71M | $99.75M | $128.10M | $59.05M | $51.55M | $57.13M | $60.19M | $117.66M | $108.98M | $143.64M | $351.41M | $368.76M | $358.79M | $169.60M | $42.86M | $52.63M | $12.71M | $5.86M | $9.24M |
| Operating Cash Flow | $128.92M | $-20.99M | $-27.77M | $-38.16M | $29.63M | $-24.71M | $-25.32M | $-23.41M | $-23.96M | $-20.60M | $-20.50M | $-27.40M | $-14.17M | $-17.79M | $-13.58M | $-13.81M | $-8.57M | $-6.89M | $-4.21M | $-3.38M |
| Capital Expenditure | $-183.00K | $-399.00K | $-2.02M | $-1.38M | $-1.69M | $-1.66M | $-6.51M | $-9.18M | $-7.27M | $-1.40M | $-2.55M | $-1.69M | $-3.06M | $-1.75M | $-2.70M | $-2.22M | $-1.19M | $-930.00K | $-1.26M | $-13.00K |
| Free Cash Flow | $128.74M | $-21.39M | $-29.79M | $-39.55M | $27.95M | $-26.36M | $-31.84M | $-32.59M | $-31.23M | $-22.00M | $-23.05M | $-29.09M | $-17.23M | $-19.55M | $-16.28M | $-16.03M | $-9.76M | $-7.82M | $-5.47M | $-3.39M |
Monte Rosa Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. It develops an oral molecular glue degrader for GSPT1, a translational termination factor and degron-containing protein for the treatment of Myc-driven cancers. The company also develops CDK2 to treat ovarian, uterine, and breast cancers; NEK7 for the treatment of inflammatory diseases, such as Crohn's disease, neurodegenerative disease, diabetes, and liver disease; VAV1, a target protein for autoimmune diseases; and BCL11A, a therapeutically-relevant protein in hemoglobinopathies. Monte Rosa Therapeutics, Inc. was incorporated in 2019 and is headquartered in Boston, Massachusetts.
$4.91
Stock Price
$302.01M
Market Cap
134
Employees
Boston, MA
Location
Revenue (FY 2024)
$75.62M
0.0% YoY
Net Income (FY 2024)
$-72.70M
46.3% YoY
EPS (FY 2024)
$-0.98
62.7% YoY
Free Cash Flow (FY 2024)
$38.01M
160.5% YoY
Profitability
Gross Margin
89.3%
Net Margin
-96.1%
ROE
-32.6%
ROA
-16.6%
Valuation
P/E Ratio
-7.06
P/S Ratio
6.78
EV/EBITDA
-4.54
Market Cap
$302.01M
Revenue & Net Income
Profit Margins
Cash Flow Summary
Operating Cash Flow
$42.00M
195.9% YoY
Free Cash Flow
$38.01M
160.5% YoY
Balance Sheet Summary
Total Assets
$438.73M
44.4% YoY
Total Debt
$42.72M
7.2% YoY
Shareholder Equity
$222.94M
-13.5% YoY
Dividend Overview
No Dividend Data
Monte Rosa Therapeutics, Inc. doesn't currently pay dividends.
Monte Rosa Therapeutics Dividends
Explore Monte Rosa Therapeutics's dividend history, including dividend yield, payout ratio, and historical payments.
Monte Rosa Therapeutics News
Read the latest news about Monte Rosa Therapeutics, including recent articles, headlines, and updates.
Monte Rosa Therapeutics Presents Preclinical Data at American Association for Cancer Research (AACR) Annual Meeting 2025 on the Potential of its CDK2-directed Molecular Glue Degrader to Treat HR-positive/HER2-negative Breast Cancer
CDK2 molecular glue degrader (MGD) in combination with CDK4/6 inhibition and anti-estrogen therapy achieved superior tumor regression in vivo compared to standard of care CDK4/6 inhibition and anti-estrogen therapy CDK2 MGD delayed resistance to CDK4/6 inhibition in vitro and displayed superior selectivity versus clinical-stage CDK2 inhibitors BOSTON, April 28, 2025 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced the company will present preclinical data on the potential of its highly selective cyclin-dependent kinase 2 (CDK2)-directed molecular glue degrader, MRT-51443, to treat HR-positive/HER2-negative breast cancer at the American Association for Cancer Research (AACR) Annual Meeting 2025, being held April 25-30 in Chicago, IL. “In preclinical models of HR-positive/HER2-negative breast cancer, the combination of MRT-51443 with a CDK4/6 inhibitor and anti-estrogen therapy drove robust tumor regressions, demonstrating notably deeper tumor responses than the standard of care combination alone,” said Sharon Townson, Ph.D.
Monte Rosa Therapeutics, Inc. (GLUE) Q4 2024 Earnings Call Transcript
Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE ) Q4 2024 Results Conference Call March 20, 2025 8:00 AM ET Company Participants Andrew Funderburk - Senior Vice President, Investor Relations and Strategic Finance Markus Warmuth - Chief Executive Officer Filip Janku - Chief Medical Officer Sharon Townson - Chief Scientific Officer Phil Nickson - Chief Business and Legal Officer Conference Call Participants Kelly Shi - Jefferies Edward Tenthoff - Piper Sandler Mark Fromm - TD Cowen Robert Driscoll - Wedbush Michael Schmidt - Guggenheim Eric Joseph - JPMorgan Operator Greetings, and welcome to Monte Rosa Therapeutics Conference Call to discuss the company's pipeline updates and clinical results. At this time, all participants are in a listen-only mode.
Monte Rosa Therapeutics Announces Fourth Quarter 2024 Financial Results and Provides Corporate Update Including New Clinical Results from MRT-6160 and MRT-2359 Programs
Results of the MRT-6160 Phase 1 SAD/MAD study demonstrate deep VAV1 degradation of greater than 90%, significant T and B cell functional inhibition as well as significant inhibition of cytokine release from T and B cells following ex-vivo stimulation, and favorable safety/tolerability profile; data support clear path to Phase 2 studies and broad potential applications in immune-mediated diseases Phase 1/2 study of MRT-2359 demonstrates encouraging signals of clinical response in castration-resistant prostate cancer (CRPC) patients resistant to AR therapy, including confirmed RECIST response; CRPC cohort will be focus moving forward with additional Phase 1/2 results expected in H2 2025; deprioritizing further expansion arms in SCLC, NSCLC and NE tumors MRT-8102, a NEK7-directed molecular glue degrader targeting diseases driven by IL-1β and the NLRP3 inflammasome, on track for IND filing in H1 2025 Strong cash position expected to fund operations into 2028 through multiple anticipated proof-of-concept clinical readouts Company to host conference call and webcast today at 8:00 a.m. ET BOSTON, March 20, 2025 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today reported a clinical update, business highlights, and financial results for the fourth quarter ended December 31, 2024.
Monte Rosa Therapeutics to Present Pipeline Update and Release Fourth Quarter and Full Year 2024 Financial Results on March 20, 2025
Company to present clinical results from Phase 1 SAD/MAD study of VAV1-directed molecular glue degrader MRT-6160 and Phase 1/2 study of MRT-2359 in MYC-driven solid tumors Conference call and webcast planned for 8 a.m. ET on March 20, 2025 BOSTON, March 11, 2025 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced that management will present a pipeline update including clinical results from its Phase 1 SAD/MAD study of the VAV1-directed MGD MRT-6160 and its Phase 1/2 study of MRT-2359 in MYC-driven solid tumors.
Monte Rosa Therapeutics to Present at the TD Cowen 45th Annual Health Care Conference
BOSTON, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced that Markus Warmuth, M.D., Chief Executive Officer, will present at the TD Cowen 45th Annual Health Care Conference on Monday, March 3, 2025, at 2:30 p.m.
Bullish On Monte Rosa Therapeutics' 'Undruggable' Targets With QuEEN
One of Monte Rosa Therapeutics' main differentiating factors is its proprietary QuEEN platform to design new molecular glue degraders. This process also leverages AI. They now have two important partnerships with Roche and Novartis, which I think validate its technology to some extent, but have also given it non-dilutive funding. Currently, its pipeline has MRT‑2359, MRT‑6160, and MRT‑8102, with key data expected in 2025.
Monte Rosa Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
BOSTON, Jan. 06, 2025 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced that Markus Warmuth, M.D., Chief Executive Officer, will present at the 43rd Annual J.P.
Monte Rosa Therapeutics Appoints Dr. Eric A. Hughes to Board of Directors
BOSTON, Dec. 13, 2024 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced the appointment of Eric A. Hughes, M.D, Ph.D.
Monte Rosa Therapeutics Presents Preclinical Data at the 2024 San Antonio Breast Cancer Symposium on the Potential of its CDK2-directed Molecular Glue Degraders to Treat HR-positive/HER2-negative Breast Cancer
Monte Rosa Therapeutics Presents Preclinical Data at the 2024 San Antonio Breast Cancer Symposium on the Potential of its CDK2-directed Molecular Glue Degr
Monte Rosa Therapeutics Announces Closing of Global License Agreement with Novartis to Advance T and B Cell-modulating VAV1-directed Molecular Glue Degraders
BOSTON, Dec. 11, 2024 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced the closing of the Company's previously announced global exclusive development and commercialization license agreement with Novartis to advance VAV1-directed MGDs, including MRT-6160. Under the terms of the agreement, Novartis will obtain exclusive worldwide rights to develop, manufacture, and commercialize MRT-6160 and other VAV1 MGDs and will be responsible for all clinical development and commercialization, starting with Phase 2 clinical studies.
Monte Rosa Therapeutics Provides Development Progress Update for Ongoing MRT-2359 Phase 1/2 Study in Patients with MYC-driven Solid Tumors
Results from dose escalation arms of Phase 1/2 study of MRT-2359 demonstrated a favorable safety profile and targeted levels of GSPT1 degradation using a 21 days on, 7 days off drug dosing schedule in heavily pretreated solid tumor patients Recommended Phase 2 dose determined as 0.5 mg daily at a 21 days on, 7 days off drug dosing schedule Additional MRT-2359 Phase 1/2 study clinical results, including biomarker and activity data, anticipated in Q1 2025 BOSTON, Dec. 05, 2024 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today reported an update from its ongoing Phase 1/2 open-label, multicenter study of MRT-2359 in patients with MYC-driven solid tumors. MRT-2359 is an investigational, orally bioavailable, GSPT1-directed MGD discovered and developed by Monte Rosa Therapeutics.
Wall Street Analysts See a 64.09% Upside in Monte Rosa Therapeutics (GLUE): Can the Stock Really Move This High?
The mean of analysts' price targets for Monte Rosa Therapeutics (GLUE) points to a 64.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Monte Rosa Therapeutics to Participate in the Piper Sandler Healthcare Conference
BOSTON, Nov. 26, 2024 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced that Markus Warmuth, M.D., Chief Executive Officer, will participate in a fireside chat at the 36th Annual Piper Sandler Healthcare Conference in New York, NY on Tuesday, December 3, 2024, at 3:30 p.m.
Wall Street Analysts Think Monte Rosa Therapeutics (GLUE) Could Surge 100.47%: Read This Before Placing a Bet
The mean of analysts' price targets for Monte Rosa Therapeutics (GLUE) points to a 100.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Wall Street Analysts Believe Monte Rosa Therapeutics (GLUE) Could Rally 67.24%: Here's is How to Trade
The average of price targets set by Wall Street analysts indicates a potential upside of 67.2% in Monte Rosa Therapeutics (GLUE). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
This Biotech Stock Has Doubled Its Value Today—Here's Why
Shares of Monte Rosa Therapeutics (GLUE) more than doubled Monday after the biotechnology company struck an exclusive development and commercialization license agreement with Novartis (NVS) for its treatments for immune system diseases that could be worth more than $2 billion.
Monte Rosa Therapeutics Announces Global License Agreement with Novartis to Advance T and B Cell-modulating VAV1-directed Molecular Glue Degraders
Agreement expected to accelerate MRT-6160 clinical development and broadly explore therapeutic opportunities across multiple indications Monte Rosa to receive up-front payment of $150 million and is eligible to receive milestone payments, U.S. profit and loss share, and tiered royalties on ex-U.S. net sales BOSTON, Oct. 28, 2024 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced a global exclusive development and commercialization license agreement with Novartis to advance VAV1 MGDs, including MRT-6160. MRT-6160 is currently in an ongoing Phase 1, single ascending dose (SAD)/multiple ascending dose (MAD) healthy volunteer study for immune-mediated conditions.
Monte Rosa Therapeutics Announces First Participants Dosed in MRT-6160 Phase 1 Study
MRT-6160, a potent and highly selective VAV1-directed molecular glue degrader, represents a potential novel therapeutic approach for systemic and neurological autoimmune and inflammatory diseases Initial Phase 1 clinical results, including biomarker data to demonstrate pharmacodynamic effects, anticipated in Q1 2025 BOSTON, Aug. 19, 2024 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced that the first participants have been dosed in a Phase 1, single ascending dose / multiple ascending dose (SAD/MAD), healthy volunteer study evaluating MRT-6160, a VAV1-directed MGD being developed for systemic and neurological autoimmune diseases. The Company expects to obtain initial data from the Phase 1 study in Q1 2025.
Monte Rosa Therapeutics Announces Second Quarter 2024 Financial Results and Provides Corporate Update
IND clearance achieved for MRT-6160, a VAV1-directed MGD in development for systemic and neurological autoimmune diseases; on track to initiate Phase 1 SAD/MAD study this summer with initial clinical data expected in Q1 2025 Ongoing Phase 1/2 Study of MRT-2359 for MYC-driven solid tumors demonstrated a favorable safety and pharmacodynamic profile at 0.5 mg with a 21 days on/7 days off schedule; dosing ongoing at 0.75 mg using a 21/7 schedule; final determination of recommended Phase 2 dose and updated clinical results anticipated in H2 2024 Achieved first program and financial milestones from strategic research collaboration with Roche Strong cash position expected to fund operations into H1 2027 and through multiple anticipated clinical readouts including from proof-of-concept patient studies for MRT-2359, MRT-6160, and MRT-8102 BOSTON, Aug. 08, 2024 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today reported business highlights and financial results for the second quarter that ended June 30, 2024. “The IND clearance of our VAV1-directed MGD MRT-6160 represents a major corporate milestone for Monte Rosa, signifying what we believe to be the first clinical-stage, rationally designed MGD for a non-oncology indication,” said Markus Warmuth, M.D.
Monte Rosa Therapeutics to Present at the UBS Targeted Protein Degradation Day
BOSTON, July 08, 2024 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced that Markus Warmuth, M.D., Chief Executive Officer, will participate in a fireside chat at the virtual UBS Targeted Protein Degradation Day on Monday, July 15, 2024, at 3:30 p.m.
Monte Rosa Therapeutics Provides Development Progress Updates on MRT-2359 and MRT-6160
Ongoing Phase 1/2 Study of MRT-2359 for MYC-driven solid tumors demonstrates favorable safety and pharmacodynamic profile dosing 0.5 mg using a 21/7 schedule; currently assessing 0.75 mg dose level; final determination of recommended Phase 2 dose and updated clinical results anticipated in H2 2024 IND submission achieved for MRT-6160, a VAV1-directed MGD in development for systemic and neurological autoimmune diseases; initiation of Phase 1 SAD/MAD study expected this summer with Phase 1 clinical data anticipated in Q1 2025 BOSTON, June 27, 2024 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced progress updates for its two lead programs, MRT-2359, an MGD being developed for MYC-driven solid tumors, and MRT-6160, a VAV1-directed MGD in development for systemic and neurological autoimmune diseases. “We are pleased with the progress of our two lead programs,” said Markus Warmuth, M.D.
Monte Rosa Therapeutics Presents Preclinical Data at EULAR 2024 Demonstrating Therapeutic Potential of MRT-6160 for the Treatment of Rheumatoid Arthritis
Monte Rosa Therapeutics Presents Preclinical Data at EULAR 2024 Demonstrating Therapeutic Potential of MRT-6160 for the Treatment of Rheumatoid Arthritis
Monte Rosa Therapeutics to Present at the Jefferies Global Healthcare Conference
BOSTON, May 30, 2024 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced that Markus Warmuth, M.D., Chief Executive Officer, will participate in a fireside chat at the Jefferies Global Healthcare Conference on Thursday, June 6, 2024, at 3:30 p.m.
Similar Companies
Related Metrics
Explore detailed financial metrics and analysis for GLUE.